NCCN has published the 20th annual edition of its NCCN Guidelines® for Small Cell Lung Cancer, marking the first 20th edition of the eight original NCCN Guidelines published in November 1996.
The National Comprehensive Cancer Network® (NCCN®) will host its 9th Annual Congress: Hematologic Malignancies™ in New York, NY, September 19 – 20, 2014.
On August 16, 2014, NCCN will host the second of two free patient information webinars designed to allow patients and their caregivers the opportunity to listen to live expert discussions about non-small cell lung cancer.
On July 10, 2014, NCCN will host the NCCN Policy Summit: The Impact of Health Care Reform on Academic Oncology Practice, at The Westin Arlington Gateway in Arlington, Virginia, as part of the NCCN Oncology Policy Program.
NCCN has launched its Reimbursement Resource App, which offers patients, providers, case managers, and payers access to payment assistance and reimbursement programs for multiple cancer types; the app is available free of charge for Apple and Android mobile devices.
The NCCN Oncology Research Program (ORP) and Pfizer Independent Grants for Learning & Change have awarded six independent grants to implement quality improvement and health care professional education in renal cell carcinoma and hematologic malignancies.
The NCCN Foundation® has awarded the fourth series of Young Investigator Awards to five young investigators from NCCN Member Institutions; the awards provide grants of $150,000 over a two-year period for research initiatives focused on assessing and improving outcomes in cancer care.
The NCCN Oncology Research Program (ORP) received a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to facilitate studies of volasertib in hematologic malignancies.
New NCCN Guidelines for Patients®: Breast Cancer Stages 0 – IV now available free-of-charge at NCCN.org/patients; NCCN Guidelines for Patients® are educational resources that offer patient-friendly treatment information.
The third annual NCCN State Oncology Society Forum, held at the NCCN 19th Annual Conference, examining the evaluation of quality in oncology, the utilization of clinical guidelines and pathways, and the consequences with the Sunshine Act.
The NCCN Oncology Research Program (ORP) received a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to facilitate studies of enzalutamide in bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.
The National Comprehensive Cancer Network® (NCCN®) will host Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies on April 25, 2014 in Bethesda, Maryland, as part of the NCCN Oncology Policy Program.
The NCCN Oncology Research Program (ORP) received a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to facilitate studies of nintedanib in colorectal and lung cancers at NCCN Member Institutions.
More than 1,300 oncology representatives attended the NCCN 19th Annual Conference, which featured presentations of the latest developments in the treatment of more than 15 cancer types, as well as two expert roundtable discussions.
The second roundtable of the NCCN 19th Annual Conference explored the Affordable Care Act (ACA) and the new-found risk that providers, payers, and patients are learning to navigate.
NCCN’s opening roundtable focused on the child’s experience when a parent has cancer, noting that honest, age-appropriate communication about cancer, its treatment, and death are beneficial at any age.
Mayo Clinic Cancer Center and Yale Cancer Center/Smilow Cancer Hospital have been named the newest NCCN Member Institutions; NCCN now has 25 Member Institutions serving patients throughout the United States.
The NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ will take place on March 13 – 15, 2014 in Hollywood, Florida; The 2014 conference features two expert roundtable discussions and clinical treatment updates for more than 15 disease types.
The NCCN Oncology Research Program (ORP) has established the NCCN Affiliate Research Consortium (ARC) to maximize collaboration between the NCCN Member Institutions and their affiliate research investigators.
JNCCN – Journal of the National Comprehensive Cancer Network named Margaret A. Tempero, MD, UCSF Helen Diller Family Comprehensive Cancer Center, as the new Editor-in-Chief, succeeding Harold J. Burstein, MD, PhD, who served in the position for five years.
NCCN, a not-for-profit alliance of 23 of the world’s leading cancer centers dedicated to improving the quality, effectiveness, and efficiency of cancer care, has appointed Gary Weyhmuller, MBA, as Executive Vice President and Chief Operating Officer (COO).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right